Novel CT-Based Objective Imaging Biomarkers of Long-Term Radiation-Induced Lung Damage
Overview
Authors
Affiliations
Purpose: Recent improvements in lung cancer survival have spurred an interest in understanding and minimizing long-term radiation-induced lung damage (RILD). However, there are still no objective criteria to quantify RILD, leading to variable reporting across centers and trials. We propose a set of objective imaging biomarkers for quantifying common radiologic findings observed 12 months after lung cancer radiation therapy.
Methods And Materials: Baseline and 12-month computed tomography (CT) scans of 27 patients from a phase 1/2 clinical trial of isotoxic chemoradiation were included in this study. To detect and measure the severity of RILD, 12 quantitative imaging biomarkers were developed. The biomarkers describe basic CT findings, including parenchymal change, volume reduction, and pleural change. The imaging biomarkers were implemented as semiautomated image analysis pipelines and were assessed against visual assessment of the occurrence of each change.
Results: Most of the biomarkers were measurable in each patient. The continuous nature of the biomarkers allows objective scoring of severity for each patient. For each imaging biomarker, the cohort was split into 2 groups according to the presence or absence of the biomarker by visual assessment, testing the hypothesis that the imaging biomarkers were different in the 2 groups. All features were statistically significant except for rotation of the main bronchus and diaphragmatic curvature. Most of the biomarkers were not strongly correlated with each other, suggesting that each of the biomarkers is measuring a separate element of RILD pathology.
Conclusions: We developed objective CT-based imaging biomarkers that quantify the severity of radiologic lung damage after radiation therapy. These biomarkers are representative of typical radiologic findings of RILD.
A Novel and Automated Approach to Classify Radiation Induced Lung Tissue Damage on CT Scans.
Szmul A, Chandy E, Veiga C, Jacob J, Stavropoulou A, Landau D Cancers (Basel). 2022; 14(5).
PMID: 35267649 PMC: 8909378. DOI: 10.3390/cancers14051341.
Quantitative Analysis of Radiation-Associated Parenchymal Lung Change.
Chandy E, Szmul A, Stavropoulou A, Jacob J, Veiga C, Landau D Cancers (Basel). 2022; 14(4).
PMID: 35205693 PMC: 8870325. DOI: 10.3390/cancers14040946.
Proton stereotactic body radiation therapy for non-small cell lung cancer.
Diwanji T, Sawant A, Sio T, Patel N, Mohindra P Ann Transl Med. 2020; 8(18):1198.
PMID: 33241047 PMC: 7576051. DOI: 10.21037/atm-20-2975.
Veiga C, Chandy E, Jacob J, Yip N, Szmul A, Landau D Radiother Oncol. 2020; 148:89-96.
PMID: 32344262 PMC: 7416106. DOI: 10.1016/j.radonc.2020.03.026.
Fenwick J, Landau D, Baker A, Bates A, Eswar C, Garcia-Alonso A Int J Radiat Oncol Biol Phys. 2019; 106(4):733-742.
PMID: 31809876 PMC: 7049901. DOI: 10.1016/j.ijrobp.2019.11.397.